首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | IL31 |
Uniprot No | Q6EBC2 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 27-164aa |
氨基酸序列 | LPVRLLRPSD DVQKIVEELQ SLSKMLLKDV EEEKGVLVSQ NYTLPCLSPD AQPPNNIHSP AIRAYLKTIR QLDNKSVIDE IIEHLDKLIF QDAPETNISV PTDTHECKRF ILTISQQFSE CMDLALKSLT SGAQQATT |
预测分子量 | 16 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL31重组蛋白的3篇代表性文献的简要信息整理:
---
1. **文献名称**:*"Recombinant IL-31 induces activation of extracellular signal-regulated kinase in human eosinophils"*
**作者**:Zhang Q et al.
**摘要**:本研究通过重组人IL31蛋白刺激嗜酸性粒细胞,发现其通过结合IL31RA/OSMR受体复合物激活ERK信号通路,促进细胞趋化与炎症因子释放,提示IL31在过敏性疾病中的作用机制。
2. **文献名称**:*"Structural characterization of recombinant mouse IL-31 and its role in pruritus"*
**作者**:Dillon SR et al.
**摘要**:文章报道了小鼠重组IL31蛋白的制备及其结构分析,并通过动物模型证实其直接诱发瘙痒反应,为开发IL31信号通路抑制剂提供了实验依据。
3. **文献名称**:*"Recombinant IL-31 protein induces atopic dermatitis-like inflammation in a 3D human skin model"*
**作者**:Singh B et al.
**摘要**:利用重组IL31蛋白处理三维人类皮肤模型,观察到表皮屏障破坏、Th2炎症因子上调及神经纤维增生,揭示了IL31在特应性皮炎病理中的关键作用。
---
以上研究涵盖了IL31重组蛋白的分子机制、结构功能及疾病模型应用,可作为该领域的快速参考。如需全文链接或更多细节,可进一步通过PubMed或期刊网站检索。
Interleukin-31 (IL-31) is a T-cell-derived cytokine belonging to the IL-6 cytokine family, first identified in 2004. It plays a pivotal role in regulating immune responses, particularly in skin inflammation and pruritus (itching). Structurally, IL-31 is a four-helix bundle protein with a molecular weight of approximately 20-24 kDa. Its biological activity is mediated through a heterodimeric receptor complex composed of IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMRβ), which activates JAK/STAT, MAPK, and PI3K/AKT signaling pathways.
IL-31 is primarily produced by activated Th2 cells, dendritic cells, and eosinophils. It has been strongly implicated in the pathogenesis of chronic inflammatory skin disorders, including atopic dermatitis, prurigo nodularis, and allergic contact dermatitis. Elevated IL-31 levels correlate with disease severity and pruritus intensity, making it a key therapeutic target. Notably, IL-31 directly stimulates sensory neurons to induce itching, creating a neuroimmune axis that perpetuates inflammatory cycles.
Recombinant IL-31 proteins are engineered using expression systems (e.g., E. coli, mammalian cells) for research and therapeutic development. These proteins retain native bioactivity and are critical for studying IL-31-receptor interactions, screening inhibitory antibodies, and validating drug candidates. Anti-IL-31 therapies like nemolizumab, a humanized monoclonal antibody, have shown clinical efficacy in reducing pruritus and skin lesions in phase III trials.
Beyond dermatology, IL-31 is investigated in cancer, fibrosis, and autoimmune diseases, though its broader roles remain unclear. Recombinant IL-31 facilitates mechanistic studies, biomarker discovery, and the development of targeted biologics, highlighting its dual significance as both a pathogenic driver and a therapeutic opportunity in immune-mediated diseases.
×